 |
| Gene And Cell Therapies Targeting CNS Disorders Market |
The Gene and Cell Therapies Targeting CNS Disorders Market encompasses therapies that targets the central nervous system (CNS) disorders such as Alzheimer's disease, Parkinson's disease, spinal cord injury, stroke, and others. The therapies involve cellular and genetic-based approaches to treat these conditions by replacing or repairing damaged or dysfunctional cells or genes in the brain or spinal cord. The therapies have advantages such as targeted treatment, reduced systemic toxicity, and regeneration potential. The market has seen growth due to increasing prevalence of CNS disorders with rising geriatric population globally.
The Global Gene and Cell Therapies
Targeting CNS Disorders Market is estimated to be valued at US$ 9.45 Mn in 2024
and is expected to exhibit a CAGR of 6.0% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Gene and Cell Therapies Targeting CNS Disorders
are Byucksan, Great Lakes Textiles, ISOVER (Saint Gobain), mJohns Manville,
Knauf Insulation, National Industrial Co., NTN OOD, Owens Corning, PGF
Insulation, Rockwool International AS, Kingspan Group, and Rosewool Insulation
Refractory Co. Ltd. Some of the key players are involved in R&D of advanced
therapies and have initiated clinical trials to evaluate the safety and
efficacy of their pipeline products.
The market provides significant opportunities for business development and
product commercialization as companies are advancing their R&D pipelines.
Furthermore, collaborations between large pharma companies and small biotechs
allows for pooling of resources to accelerate development.
On the global front, companies are expanding their business operations in
emerging markets of Asia Pacific, Middle East, and Latin America through
partnerships and direct investments. This allows them to tap into markets with
high unmet needs and potential for future growth.
Market drivers and restrain
The major market driver is the rising prevalence of CNS disorders worldwide.
According to WHO, over 1 billion people are affected by neurological disorders
globally with significant increase anticipated in low and middle income
countries. This is creating a massive patient pool requiring innovative
therapies to manage their conditions.
However, high costs associated with development and manufacturing of cell and
gene therapies is a major restrain. Given the complexities involved, costs runs
into several millions of dollars before approval and commercialization. This
poses significant financial challenges for companies especially smaller players
and limits accessibility of these advanced treatment options.
Segment Analysis
Genetic disorders dominated the gene and cell therapies targeting CNS disorders
market owing to rising incidence of genetic neurological disorders like
Alzheimer's disease, Huntington disease, Parkinson's disease, etc. Gene
therapies for neurodegenerative diseases like Alzheimer's holds major potential
due to lack of effective treatment options. Cell therapies are gaining traction
for treating neurodegenerative indications given its capacity for regeneration
of damaged tissue and suppression of inflammation. Stem cell-based therapies
are one of the key focus areas of research for treating many CNS disorders.
Global Analysis
North America dominates the Gene
And Cell Therapies Targeting CNS Disorders Market Demand due to well-developed healthcare
infrastructure, rising R&D investments for neuroscience, and presence of
key industry players. The Europe market is expected grow at a significant rate
during the forecast period supported by increasing funding for CNS research.
Asia Pacific is likely to offer lucrative market opportunities owing to rising
healthcare expenditure, growing incidence of neurological disorders, and
improving research landscape. Growing focus on developing novel therapies for
neurodegenerative indications and rising government support are augmenting the
industry growth across all regions.
0 Comments